 Actinium Pharmaceuticals NYSEAMERICAN:ATNM was upgraded by Zacks Investment Research from a hold rating to a buy rating in a report released on Monday, Zacks.com reports. The firm currently has a 0.50 price target on the biotechnology companys stock. Zacks Investment Researchs price objective would indicate a potential upside of 19.13 from the stocks previous close. ... 